Hepatitis Market Research Reports & Industry Analysis

The notion “hepatitis” means inflammation of the liver or its cells, often caused by some virus and accompanied in its initial phase to by symptoms similar to flu: fever, loss of appetite, muscle/joint aches, etc. According to the virus type hepatitis is divided into several types: hepatitis A, В C, D and E. Hepatitis can disappear on its own, but in some cases it can lead to serious liver dysfunctions and severe complications such as fibrosis, liver failure or cancer, cryoglobulinemia, an a lot more.

The world hepatitis drugs market has experienced stable growth over the recent years, driven by the constant increase of demand from developed countries, introduction of new products and technological advancement in the medical industry. It is set to continue growing at a CARG of above 12% through 2015. Gilead Sciences, Merck & Co., GlaxoSmithKline, Bristol-Myers Squibb and Hoffmann-La Roche are amid the key hepatitis market players.

The collection of the research reports found in this catalogue provides an extensive insight into the hepatitis market at different geographical scales. Relevant information on the market size, share, segmentation as well as major factors influencing the market is presented in the researches. The reports offer detailed assessment of the competitive landscape and profile top companies. In addition, discussions of future market prospects for the are at hand in the research reports.

Found 77 publications
2014 Analysis of the UK Hepatitis Diagnostics Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices - Supplier Shares and Sales Forecasts For 10... US$ 3,900.00

Complete report $3,900 . DataPack (test volumes, sales forecasts, supplier shares) $2,500. The report presents a detailed analysis of the Hepatitis diagnostics market in the UK. Current scientific views on the Hepatitis definition, epidemiology and etiology are reviewed. The report provides five-year test ...

Feb, 2014 241 pages
2014 Analysis of the Spanish Hepatitis Diagnostics Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices - Supplier Shares and Sales Forecasts For 10... US$ 3,900.00

Complete report $3,900 . DataPack (test volumes, sales forecasts, supplier shares) $2,500. The report presents a detailed analysis of the Hepatitis diagnostics market in Spain. Current scientific views on the Hepatitis definition, epidemiology and etiology are reviewed. The report provides five-year test ...

Feb, 2014 241 pages
2014 Analysis of the Italian Hepatitis Diagnostics Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices - Supplier Shares and Sales Forecasts For 10... US$ 3,900.00

Complete report $3,900 . DataPack (test volumes, sales forecasts, supplier shares) $2,500. The report presents a detailed analysis of the Hepatitis diagnostics market in Italy. Current scientific views on the Hepatitis definition, epidemiology and etiology are reviewed. The report provides five-year test ...

Feb, 2014 241 pages
2014 Analysis of the German Hepatitis Diagnostics Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices - Supplier Shares and Sales Forecasts For 10... US$ 3,900.00

Complete report $3,900 . DataPack (test volumes, sales forecasts, supplier shares) $2,500. The report presents a detailed analysis of the Hepatitis diagnostics market in Germany. Current scientific views on the Hepatitis definition, epidemiology and etiology are reviewed. The report provides five-year ...

Feb, 2014 241 pages
2014 Analysis of the French Hepatitis Diagnostics Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices - Supplier Shares and Sales Forecasts For 10... US$ 3,900.00

Complete report $3,900 . DataPack (test volumes, sales forecasts, supplier shares) $2,500. The report presents a detailed analysis of the Hepatitis diagnostics market in France. Current scientific views on the Hepatitis definition, epidemiology and etiology are reviewed. The report provides five-year test ...

Feb, 2014 241 pages
2014 Analysis of the Japanese Hepatitis Diagnostics Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices - Supplier Shares and Sales Forecasts For 10... US$ 3,900.00

Complete report $3,900 . DataPack (test volumes, sales forecasts, supplier shares) $2,500. The report presents a detailed analysis of the Hepatitis diagnostics market in Japan. Current scientific views on the Hepatitis definition, epidemiology and etiology are reviewed. The report provides five-year test ...

Feb, 2014 241 pages
Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape US$ 3,500.00

... 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape Summary GBI Research, has released the pharma report, “Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to ...

Jan, 2014 120 pages
Therapy Class Overview : Hepatitis C Virus Infection US$ 1,000.00

... (PhIII) and AbbVie/ Enanta’s (ABT-450r/ABT-472/ABT-333) should remove the need of IFN for GT1 genotype HCV patients as well! Tapping the ... and ROW opportunity Competitive Landscape - IFN-Free drugs HCV Vaccines and their progress Difficult to treat and drugs for HCV-HIV co infection Market size opportunity ...

Oct, 2013 33 pages
2014 Strategies for the European Hepatitis Diagnostic Testing Market US$ 6,900.00

... leading suppliers and recent market entrants developing innovative technologies and products; and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning issues and concerns. Contains 295 pages and 67 tables

Jan, 2014 295 pages
2014 Strategies for the US Hepatitis Diagnostic Testing Market US$ 3,900.00

... leading suppliers and recent market entrants developing innovative technologies and products; and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning issues and concerns. Contains 241 pages and 14 tables

Jan, 2014 241 pages
US Hepatitis Diagnostics Market 2014: Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices--Supplier Shares and Sales Forecasts For 10 Immunodiagnostic and NAT... US$ 3,900.00

... , sales forecasts, supplier shares) $2,500. The report presents a detailed analysis of the Hepatitis diagnostics market in the US. Current scientific views on the ... HBV NAT , HBs Ag, HCV , Anti-HBc , Anti-HBs , Anti-HAV , Hepatitis Delta , HBc Ag , HBe Ag , and ALT/SGPT tests performed in the ...

Jan, 2014 241 pages
Hepatitis C: Game changing regimens to revolutionise treatment landscape - KOL Insight US$ 4,995.00

... will shape the future market. Key Benefits Therapy Trends: Hepatitis C -- Game changing regimens to revolutionise treatment landscape examines the most prominent ... clinical research trends do KOLs predict for future HCV therapies? Hepatitis C’s Panel of Key Opinion Leaders FirstWord selected the KOLs for ...

Apr, 2014 163 pages
Hepatitis C: Game changing regimens to revolutionise treatment landscape - Consensus Outlook US$ 4,995.00

... reports and data analysis files delivered to your inbox after each significant market event. Key Benefits Therapy Trends Consensus Outlook: Hepatitis C provides: Evaluate future sales forecasts and predicted market growth Map your market parameters and chart commercial prospects Assess market share by ...

Dec, 2013
European Hepatitis Diagnostics Market 2014: Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices--Supplier Shares and Sales Forecasts For 10 Immunodiagnostic and... US$ 6,900.00

... , supplier shares) $4,500. The report presents a detailed analysis of the Hepatitis diagnostics market in Europe, (France, Germany, Italy, Spain, UK). Current scientific views on the ... , HBV NAT, HBs Ag, HCV, Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag, HBe Ag, and ALT/SGPT tests performed in the ...

Jan, 2014 295 pages
2014 Opportunities in the US Hepatitis Diagnostic Testing Market US$ 3,900.00

... analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning issues and concerns. Contains 241 ...

Dec, 2013 241 pages
Physician Views: Entering the post-interferon era – will Gilead Sciences dominate hepatitis C? US$ 645.00

... point to 2015 forecast hepatitis C sales for Gilead being 10 times those currently anticipated for AbbVie. To gain a better perspective on how physicians expect to use interferon-free regimens, FirstWord is polling gastroenterologists/hepatologists and infectious disease specialists based in the US and EU5. ...

Nov, 2013
2014 Analysis of the European Hepatitis Diagnostics Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices - Supplier Shares and Sales Forecasts For 10... US$ 6,900.00

Complete report $6,900. DataPack (test volumes, sales forecasts, supplier shares) $4,500. The report presents a detailed analysis of the Hepatitis diagnostics market in Europe, (France, Germany, Italy, Spain, UK). Current scientific views on the Hepatitis definition, epidemiology and etiology are reviewed. ...

Nov, 2013 295 pages
2014 Analysis of the US Hepatitis Diagnostics Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices - Supplier Shares and Sales Forecasts For 10... US$ 3,900.00

Complete report $3,900. DataPack (test volumes, sales forecasts, supplier shares) $2,500. The report presents a detailed analysis of the Hepatitis diagnostics market in the US. Current scientific views on the Hepatitis definition, epidemiology and etiology are reviewed. The report provides five-year test ...

Nov, 2013 241 pages
Vaniprevir (Hepatitis C Virus) - Forecast and Market Analysis to 2022 US$ 3,495.00

Vaniprevir (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in ... a SWOT analysis. Sales forecast for Vaniprevir for the top nine countries from 2012 to 2022. Sales information covered for the US, France, ...

May, 2013 48 pages
Sofosbuvir and Sofosbuvir/Ledipasvir (Hepatitis C Virus) - Forecast and Market Analysis to 2022 US$ 3,495.00

... and Sofosbuvir/Ledipasvir (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) ... as well as a SWOT analysis. Sales forecast for Sofosbuvir and Sofosbuvir/Ledipasvir for the top nine countries from 2012 to 2022. Sales ...

May, 2013 55 pages
Simeprevir (Hepatitis C Virus) - Forecast and Market Analysis to 2022 US$ 3,495.00

Simeprevir (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in ... a SWOT analysis. Sales forecast for Simeprevir for the top nine countries from 2012 to 2022. Sales information covered for the US, France, ...

May, 2013 51 pages
Faldaprevir and BI 207127 (Hepatitis C Virus) - Forecast and Market Analysis to 2022 US$ 3,495.00

Faldaprevir and BI 207127 (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) ... well as a SWOT analysis. Sales forecast for Faldaprevir and BI 207127 for the top nine countries from 2012 to 2022. Sales information covered ...

May, 2013 51 pages
Daclatasvir, Asunaprevir, and Peginterferon Lambda (Hepatitis C Virus) - Forecast and Market Analysis to 2022 US$ 3,495.00

... , etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on Daclatasvir, Asunaprevir, and Peginterferon Lambda including product description, safety and efficacy profiles as well as a SWOT analysis. Sales forecast for ...

May, 2013 52 pages
AbbVie’s Combination Therapy: ABT-450, ABT-333, and ABT-267 (Hepatitis C Virus) - Forecast and Market Analysis to 2022 US$ 3,495.00

AbbVie’s Combination Therapy: ABT-450, ABT-333, and ABT-267 (Hepatitis C Virus) - Forecast and Market Analysis to 2022 Summary Hepatitis C ... , itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. AbbVie is developing an interferon-free HCV regimen that ...

May, 2013 50 pages
Hepatitis C Drug Pipeline Analysis US$ 1,800.00

... their key competitor in the industry. Following parameters for each drug profile in development phase are covered in “Hepatitis C Drug Pipeline Analysis” research report: Drug Profile Overview Active Indication Phase of Development Country for Clinical Trial Owner / Originator/ Licensee/Collaborator ...

Aug, 2013 700 pages
Hepatitis Drugs and Vaccines: World Market 2013-2023 US$ 2,635.00

... . What prospects for regions and countries? Developments worldwide expand the hepatitis products market, especially rising demand for medicines in emerging countries. ... you possibilities, helping you stay ahead. Nine ways Hepatitis Drugs and Vaccines: World Market 2013-2023 helps you To sum up, our ...

Jun, 2013 197 pages
Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide US$ 2,090.00

... C virus (HCV) has been discovered so far the market is driven by therapeutics. The increase in the prevalence of the disease and the availability ... HCV have been identified as a formidable challenge to prevention and care. Renub Research study titled “Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, ...

Jul, 2013 164 pages
Hepatitis D - Pipeline Review, H1 2014 US$ 2,000.00

Summary Global Markets Direct’s, ‘Hepatitis D - Pipeline Review, H1 2014’, provides an overview of the Hepatitis D’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hepatitis D, complete with comparative analysis at various stages, therapeutics ...

Jun, 2014 31 pages
Hepatitis B - Pipeline Review, H1 2014 US$ 2,000.00

Summary Global Markets Direct’s, ‘Hepatitis B - Pipeline Review, H1 2014’, provides an overview of the Hepatitis B’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hepatitis B, complete with comparative analysis at various stages, therapeutics ...

May, 2014 297 pages
EpiCast Report: Hepatitis C Virus - Epidemiology Forecast to 2022 US$ 3,995.00

EpiCast Report: Hepatitis C Virus - Epidemiology Forecast to 2022 Summary Hepatitis C is a largely asymptomatic liver disease caused by the hepatitis C virus (HCV). HCV ... associated with injection drug use, which accounts for up to 60% of all reported HCV cases (ECDC, 2010). China and Brazil’s prevalent HCV ...

Mar, 2013 58 pages
Hepatitis – Pipeline Review, H1 2013 US$ 2,000.00

... key players involved in the therapeutic development for Hepatitis. Hepatitis - Pipeline Review, Half Year is built using data and information sourced ... on the basis of route of administration and molecule type. Key discontinued pipeline projects. Latest news and deals relating to the products. Reasons to ...

Mar, 2013 527 pages
Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019 US$ 3,995.00

... the industry analysis specialist, has released its new report, “Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential ... data from 2006 to 2011, forecast for eight years to 2019. Pipeline analysis data providing a split across the different phases, mechanisms ...

Mar, 2012 103 pages
Hepatitis C - Pipeline Review, H1 2014 US$ 2,500.00

Summary Global Markets Direct’s, ‘Hepatitis C - Pipeline Review, H1 2014’, provides an overview of the Hepatitis C’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hepatitis C, complete with comparative analysis at various stages, therapeutics ...

Feb, 2014 722 pages
Therapeutic Class Report Overview : Hepatitis C Virus Infection US$ 1,000.00

... bar and the expectations of pts, physicians and investors. Freedom from IFN, treating all genotypes and betting on vaccines could bring a sea of change in the HCV therapy class area in the future. Roche set the trend with the acquisition of Anadys for total of $230m followed by GILD buying VRUS for $11b, ...

Feb, 2013 31 pages
Therapy Trends Consensus Outlook: Hepatitis C US$ 4,995.00

... introduction more effective and tolerable pipeline agents. Therapy Trends Consensus Outlook: Hepatitis C analyses the global HCV market players and ... results to in-depth discussions with leading key opinion leaders (KOLs). Consensus forecasts also act as an excellent benchmark against which other projections ...

Dec, 2012
KOL Insight: Hepatitis C: the Race for the First Interferon-free Regimen US$ 4,995.00

... market. Key Benefits Hepatitis C: the race for the first interferon-free regimen examines the most prominent insights gained from ... markets in other countries. In order to critically select Key Opinion Leaders (KOLs) a number of parameters were considered including their clinical experience, scientific ...

Nov, 2012 246 pages
Hepatitis C Therapeutics Market to 2018 - Expected Launch of GS-7977 in 2015 will Pave the Way for an Oral Interferon-free Combination Therapy US$ 3,500.00

... and explores the competitive landscape, including major players in the hepatitis C therapeutics market. Finally, the report also includes analysis of the Mergers and ... launch of oral DAA molecules, the first of which should be in the market in 2015. Further, combinations of DAA drugs will improve the overall ...

Oct, 2012 113 pages
Global Hepatitis Testing Market, 2010-2018 (DataPack) US$ 5,520.00

... US, Europe (France, Germany, Italy, Spain, UK) and Japan. The report provides the 2010-2018 test volume and sales forecasts for HAV NAT, HBV NAT, HBs Ag, HCV ... in addition to test volume and sales projections, the report presents the 2010 sales and market share estimates for major suppliers of Hepatitis tests.

Jul, 2012
Hepatitis Partnering 2009-2014 US$ 995.00

... by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink ... royalty data The leading hepatitis deals by value since 2009 In Hepatitis Partnering 2009-2014, the available deals are listed by: Headline ...

Apr, 2014 100 pages
Hepatitis D – Pipeline Review, H2 2012 US$ 2,000.00

... key players involved in the therapeutic development for Hepatitis D. Hepatitis D - Pipeline Review, Half Year is built using data and information sourced ... on the basis of route of administration and molecule type. Key discontinued pipeline projects. Latest news and deals relating to the products. Reasons ...

Dec, 2012 47 pages
Hepatitis C Global Clinical Trials Review, H2, 2011 US$ 1,000.00 Oct, 2011 132 pages
Hepatitis B Global Clinical Trials Review, H2, 2011 US$ 1,000.00 Nov, 2011 119 pages
Competitor Analysis: Targeted Therapy of Hepatitis C US$ 826.00

Product description The present Competitive Intelligence Report about Targeted Therapy of Hepatitis C provides a competitor evaluation in the field of specifically targeted antiviral therapeutics for hepatitis C (STAT-C) as of August 2011. Purchase of the downloadable pdf report includes a 6-month online ...

Aug, 2011 91 pages
Hepatitis A Global Clinical Trials Review, Q2, 2011 US$ 1,000.00 Jun, 2011 46 pages
Hepatitis C Global Clinical Trials Review, Q2, 2011 US$ 1,000.00 Jun, 2011 84 pages
Hepatitis B Global Clinical Trials Review, Q2, 2011 US$ 1,000.00 Jun, 2011 81 pages
1 2 >
Skip to top